Latest News
Get real-time updates on the latest news and developments in the pharmaceutical world. Stay informed about new drug launches, research findings, regulatory changes, and industry updates. Explore a wide range of topics and stay connected with the rapidly evolving world of pharma.
Evident Vascular to launch AI-powered IVUS platform for peripheral vascular imaging
unveiling its next strategic move with Evident Vascular, a startup incubated under its guidance. Evident Vascular has emerged from stealth ...
J&J’s drug combo challenges AZ’s Tagrisso in lung cancer, but faces hurdles
In a high-stakes battle, Johnson & Johnson’s drug combination of Rybrevant and the Lazertinib, developed in partnership with Yuhan, has ...
Emergent hires former NFL player to raise opioid awareness at college football events
Emergent BioSolutions is on a mission to promote its life-saving opioid overdose treatment, Narcan, and has enlisted former NFL star ...
Ardelyx wins FDA approval for Xphozah, a new drug for chronic kidney disease
Ardelyx’s perseverance pays off as the FDA grants approval for its groundbreaking medication, Xphozah (tenapanor), marking the third attempt as ...
VedaBio raises $40 million to develop CRISPR-based diagnostics
A groundbreaking venture, VedaBio, has emerged from stealth mode with an ambitious vision of advancing CRISPR technology to new heights. ...
J&J confident in new products as Stelara faces biosimilar threat
In the third quarter of 2023, Johnson & Johnson (J&J) exceeded analyst expectations, solidifying its position as a pharma and ...
Neurology patient groups rate pharma higher, but some big players lose rank
The pharmaceutical industry’s reputation among neurology patient groups has undergone a notable transformation, marking the third consecutive year of positive ...
Aldeyra faces FDA rejection risk for dry eye drug due to review issues
Aldeyra Therapeutics confronts a daunting situation as regulatory concerns cast doubt on the future of its dry eye disease medication, ...
Siemens Healthineers and Qure.ai to deploy AI-powered chest X-ray screening for TB
Siemens Healthineers, in collaboration with Qure.ai and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, is intensifying efforts to ...
SpliceBio and Roche’s Spark Therapeutics team up for eye disease gene therapy
SpliceBio Initiates $216 Million Collaboration with Roche’s Gene Therapy Unit to Pave the Way for Innovative Inherited Retinal Disease Treatment ...
Gilead strikes $100 million deal with Assembly Bio for antiviral assets
Gilead Sciences is taking a unique approach to secure early access to Assembly Biosciences’ promising programs. Instead of an outright ...
Evelo seeks new partner after microbiome platform fails to beat placebo
In a series of unfortunate turns, Evelo Biosciences, a biotech company backed by Flagship Ventures and that went public in ...
Roche partners with Monte Rosa to develop molecular glue drugs for cancer
In a dynamic move, Roche has forged its second major agreement in the realm of molecular glue technology, this time ...
Keytruda approved by FDA for early-stage lung cancer surgery, with a twist
In a groundbreaking development, the FDA has granted approval for Merck’s Keytruda to be employed in a continuous immunotherapy regimen ...
CMS proposes to cover more PET scans for Alzheimer’s disease diagnosis
This year, promising drug treatments for Alzheimer’s disease have emerged, prompting the Centers for Medicare and Medicaid Services (CMS) to ...
Better Therapeutics launches digital app to help Type 2 diabetes patients
Better Therapeutics is officially launching its digital therapeutic app, AspyreRx, for managing Type 2 diabetes after securing FDA de novo ...
Bristol Myers Squibb’s Opdivo gets FDA approval for early-stage melanoma
Bristol Myers Squibb’s Opdivo has achieved a significant milestone with a new FDA approval that expands its reach into earlier ...
Pfizer Reduces Revenue Projection by $9 Billion Due to Declining COVID Sales, Prepares for Substantial Cost Reductions
As the COVID-19 pandemic transitions into an endemic phase, pharmaceutical companies have been bracing for a decline in demand for ...
AbbVie’s Skyrizi beats J&J’s Stelara in head-to-head Crohn’s disease trial
AbbVie’s Skyrizi has notched a resounding victory over Johnson & Johnson’s biologic drug Stelara in treating Crohn’s disease, as revealed ...
Concentra makes a bid to buy Rain Oncology, a struggling biotech with two cancer drugs
Concentra Biosciences, having weathered a failed acquisition of Atea Pharmaceuticals earlier this year, has now turned its attention to Rain ...
Novo Nordisk acquires Corvidia Therapeutics for $1.3B to compete with Bayer’s Kerendia
Novo Nordisk, riding high on the success of its semaglutide sales, has taken a strategic leap by investing up to ...
Merck KGaA launches campaign to educate doctors on rare MS type, challenging Sanofi
Merck KGaA is gearing up for a significant milestone in the development of its multiple sclerosis (MS) drug candidate. As ...
Sotio inks $740M deal with Synaffix for ADC technology after lead drug setback
In a strategic move following the recent setback in its IL-15 asset trials, Sotio Biotech has embarked on an ambitious ...
Omeros halts phase 3 trial of kidney disease drug after disappointing results, stock plummets
In a surprising turn of events, Omeros has halted its phase 3 trial of narsoplimab in kidney disease patients, as ...
Lonza to create over 100 jobs in Switzerland with new antibody filling line and expanded collaboration
In a series of recent strategic moves, Lonza, the prominent Swiss Contract Development and Manufacturing Organization (CDMO), is making headlines. ...
Relay postpones its rare cancer drug approval plans due to IRA, losing ground to competitors
Relay Therapeutics is altering its strategic course, driven by the effects of the Inflation Reduction Act (IRA), leading the biotech ...
FDA warns J&J’s Abiomed over quality issues with Impella heart pumps and software
The FDA has taken significant steps in its response to safety concerns surrounding certain Abiomed heart pumps. Following several Class ...
Sotio halts trials of IL-15 drug in solid tumors due to lack of efficacy, casting doubt on cytokine’s potential
Sotio Biotech has decided to halt ongoing studies of its IL-15 superagonist, nanrilkefusp alfa, due to insufficient efficacy in clinical ...
Roche’s BTK inhibitor shows potential to cross blood-brain barrier in MS trial
Roche is touting its multiple sclerosis (MS) drug as a potential game-changer in the field, asserting that it has achieved ...
Novo Nordisk raises its 2023 outlook for sales and profit, driven by strong diabetes and obesity drugs
Novo Nordisk is experiencing a remarkable surge in its fortunes, primarily driven by the widespread popularity of its diabetes medication ...
